Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Brazil, Mexico, Philippines among those due to get Pfizer shots from COVAX in Q2 - statement

04/12/2021 | 08:35am EDT

GENEVA, April 12 (Reuters) - Some 14.1 million doses of the Pfizer BioNTech COVID-19 vaccine have been allocated to 47 countries and economies for delivery in the second quarter of this year, the Gavi Vaccine Alliance said on Monday.

Brazil, Colombia, Mexico, the Philippines, South Africa, and Ukraine are set to be among the main recipients of the Pfizer vaccine between April and June, according to Gavi, which co-leads the COVAX facility with the World Health Organization (WHO) and other partners.

The COVAX programme offers a lifeline to low-income countries in particular, allowing them to inoculate health workers and others at high risk, even if their governments have not managed to secure vaccines from the manufacturers.

Australia, Britain, Kuwait, and the United Arab Emirates are due to receive their first shots via COVAX with the Pfizer doses, which is "based on current knowledge of COVID-19 vaccine supply availability", Gavi said in a statement.

The programme delivered nearly 38.4 million doses of COVID-19 vaccines to 102 countries across six continents, six weeks after it began to roll out supplies, Gavi said last Thursday.

Deliveries of the AstraZeneca vaccine to 142 participants under a previously announced round were underway, "with some delays" that may extend deliveries past May, Gavi said on Monday.

Reduced availability delayed some deliveries in March and April, and much of the output of the Serum Institute of India, which makes the AstraZeneca vaccine, is being kept in India, where the number of daily infections is spiralling.

The chief executive of Gavi, Seth Berkley, said last Friday that COVAX aimed to deliver one third of a billion COVID-19 doses by mid-year, on the way to more than 2 billion in 2021.

(Reporting by Stephanie Nebehay; Editing by Raissa Kasolowsky)

© Reuters 2021
All news about ASTRAZENECA PLC
05/07Correction to Impact of U.S. Support for Patent Waiver on Vaccine Makers Arti..
05/07ASTRAZENECA PHARMA INDIA  : Key EU countries rebuff Biden on sharing COVID vacci..
05/07AstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emerge..
05/07AstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emerge..
05/07MARKET CHATTER : WHO's Director General Calls for Countries to Support Waiving C..
05/07U.S. Support for Patent Waiver Unlikely to Cost Covid-19 Vaccine Makers in Sh..
05/07How the U.S. locked up vaccine materials other nations urgently need
05/07WHO Endorses China's Covid-19 Vaccine Sinopharm -- 4th Update
05/07ASTRAZENECA  : WHO panel OKs emergency use of China's Sinopharm vaccine
05/07SINOVAC BIOTECH  : WHO gives emergency approval to first Chinese COVID-19 vaccin..
More news
Financials (USD)
Sales 2021 30 843 M - -
Net income 2021 4 575 M - -
Net Debt 2021 11 038 M - -
P/E ratio 2021 29,9x
Yield 2021 2,64%
Capitalization 142 B 142 B -
EV / Sales 2021 4,96x
EV / Sales 2022 4,35x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Average target price 130,07 $
Last Close Price 108,20 $
Spread / Highest target 53,4%
Spread / Average Target 20,2%
Spread / Lowest Target -12,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON7.07%441 726
ROCHE HOLDING AG-3.06%284 771
PFIZER, INC.6.47%218 608
ABBVIE INC.8.03%204 861
MERCK & CO., INC.-4.14%196 943